Typ 1 diabetes

The Bright study demonstrated similar efficacy and safety of Toujeo^® (Glargine 300) compared to degludec (insulin degludec) in type 2 diabetes patients who had not previously received basal insulin¹.

DELIVER-G: Real-world analysis in insulin-naïve adults with T2DM on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†1

RESTORE-G: Real-world analysis in insulin-naïve adults with T2D on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†2

Anti-islet autoantibodies that target proteins associated with beta-cells serve as biomarkers of autoimmune type 1 diabetes (T1D) development.¹ The number of detectable autoantibodies through screening correlates with risk of developing autoimmune T1D.² Assays for detecting autoimmune T1D have shown high sensitivity and specificity.^3,4

På den här sidan kan du lära dig mer om diabetes och träning, både vid typ 1 och typ 2.

Injektionsfilm för din patient som behandlas med Toujeo DoubleStar